Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A Jonas, MD PhD, Aaron C. Logan, MDPhDMPhil, Deepa Jeyakumar, MD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Matthew J. Wieduwilt, Leslie G. Oesterich, MD, Peter T. Curtin, MD

Blood (2017) 130 (Supplement 1): 2973.

https://doi.org/10.1182/blood.V130.Suppl_1.2973.2973

Published: 2017

Journal Articles

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Jose F. Leis, MD, PhD, Keith S. Hansen, MD, Peter T. Curtin, MD, Brandon M. Hayes-Lattin, MD, Keith S. Lanier, MD, Nathan R. Stanton, Charles D. Callaway, Ceder J. Fowler, Adam M. Dunn, Daniel Gruenberg, MD, Michael J. Mauro, MD, Gerald M. Segal, MD, Lisa K. Hansen, Jeffrey I. Menashe, MD, Tibor J. Kovacsovics, MD, Aleksandra Simic, MD, Richard T. Maziarz, MD.

Blood (2005) 106 (11): 5509.

https://doi.org/10.1182/blood.V106.11.5509.5509

Published: 2005

Journal Articles

Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Brandon Hayes-Lattin, MD, Pritesh Mehta, Adam Dunn, Nan Subbiah, Jose F. Leis, MD, PhD, Aleksandra Simic, MD, Bryon Allen, Suzanne Balliesen, Peter T. Curtin, MD, Elliot Epner, MD, PhD, William H. Fleming, MD, PhD, Carol Jacoby, Michael J. Mauro, MD, Craig R. Nichols, MD, Susan Schubach, Richard T. Maziarz, MD

Blood (2004) 104 (11): 5237.

https://doi.org/10.1182/blood.V104.11.5237.5237

Published: 2004

Journal Articles

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Brandon Hayes-Lattin, MD, Joseph Bubalo, PharmD, Adam Dunn, Nan Subbiah, Bryon Allen, Suzanne Balleisen, Peter T. Curtin, MD, Carol Jacoby, Jose F. Leis, MD, PhD, Michael J. Mauro, MD, Aleksandra Simic, MD, Susan Schubach, Richard T. Maziarz, MD

Blood (2004) 104 (11): 5093.

https://doi.org/10.1182/blood.V104.11.5093.5093

Published: 2004

NARROW

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They?.

Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.

Safety and Tolerability of Anti-Bacterial Prophylaxis during the Post-Engraftment Phase after Myeloablative Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only